Genic is a cosmetics manufacturer built around hydrogel mask packs applied to the skin, with a lineup that extends to sheet mask packs and skincare. Although classified under chemicals, in practice its revenue comes from selling its own brands and from making and supplying products to order for client companies, and because its market cap is not large, changes such as adoption of new products flow into results relatively quickly. Its 2025 results reached annual revenue of ₩78.2 billion, operating profit of ₩15.0 billion and net profit of ₩18.9 billion - up sharply from the prior year - and in Q1 2026 it posted revenue of ₩29.4 billion, operating profit of ₩3.4 billion and net profit of ₩3.5 billion. What stands out lately is that, after turning profitable, revenue has grown more than 50% for two straight years, and with the efficiency of a 46% ROE and a 19% operating margin at a trailing P/E of 8.92x the valuation burden is not heavy - a strength. The caution is that if mask-pack demand cools or orders wobble on reliance on a particular client, volatility can rise.

At-a-glance assessment financial health · growth · profitability · valuation

Financial healthStable
  • Debt ratio, current ratio and interest burden all look healthy.
GrowthGrowing
  • Revenue rose 56.7% year over year, and the pace is slowing (3-year trend: rising).
  • Most recent quarter (Q1 2026) revenue was 64.7% higher than a year earlier.
ProfitabilityStrong
  • ROE is 46.0% (total-net basis). It is above the sector average.
  • Operating margin is 19.1%.
ValuationUndervalued
  • The P/E sits below the sector median.

Ownership & governance As of 2025-12-31

Largest shareholder Soulbrain Holdings 34.55% (corporate)

Controlling bloc incl. related parties 34.55%

With the controlling bloc holding 35%, the ownership structure is stable.

🔎 In-depth analysis

🏢Business
  • Genic is a cosmetics manufacturer built around hydrogel mask packs applied to the skin, with a lineup that extends to sheet-type mask packs and skincare products.
  • Although classified under chemicals, in practice its revenue comes from making mask packs and supplying them to cosmetics brands and distributors.
  • Its hydrogel products sell steadily on the strength of quality and price competitiveness, and it also produces and supplies items in the forms clients want, such as the wrapping-type mask packs whose demand has grown recently.
  • In other words, the basis of revenue is a structure of both selling its own brands and manufacturing to client orders for supply.
  • Because its market cap is not large, changes such as adoption of new products or landing a major client flow into results relatively quickly.
📈Price & chart
  • The latest close is ₩27,900 and the market cap is ₩222.3 billion.
  • The price sits above its 20-day line (₩22,918) and above its 60-day line (₩24,352).
  • Above both its short- and mid-term moving averages, the trend is on the favorable side.
  • The RSI (a supplementary gauge that weighs upward against downward momentum over the past 14 days on a 0-100 scale) is 64.8, a neutral level.
  • The price is up 24.3% over one month and up 2.8% over three months, and stands 31.3% below its 52-week high.
  • Its relative strength versus the KOSDAQ is 87 (on a 1-99 scale that converts return against the index over the past year with more weight on recent performance; higher means stronger than the market), placing it in roughly the top 13% of all stocks by strength.
  • Over the past three months it outpaced the index by 36.8%.
  • Chart readings are best viewed alongside trading volume and disclosure dates.
📊Key metrics
  • The most recent annual revenue is ₩78.2 billion, operating profit ₩15.0 billion and net profit ₩18.9 billion, with an operating margin of 19.1% and a net margin of 24.2% - thick margins.
  • ROE (how much is earned in a year on equity) is 46.0%, well above the peer average, while the debt ratio (debt against equity) is 137.7%, the current ratio (assets convertible to cash against debt due within a year) is 237%, and interest coverage (how many times operating profit covers interest) is 45.5x, so the finances are stable.
  • The trailing P/E (how many times the past year's earnings the price represents) is low at 11.77x, while the P/B (how many times book value the price represents) of 5.42x looks high on the number alone.
  • But the reason the P/B is high is that it earns 46% on equity - not that the price is excessive.
  • For a stock whose profit has just turned up from loss to gain, future profit matters more than past results, and the forward P/E is at a level similar to peers.
🚀Growth
  • Revenue rose sharply for two straight years - ₩28.1 billion in 2023, ₩49.9 billion in 2024 (up 77.8%), and ₩78.2 billion in 2025 (up 56.7%) - and operating profit turned clearly around, from a ₩4.0 billion loss in 2023 to ₩6.0 billion in 2024 and ₩15.0 billion in 2025.
  • The key is that margins have kept thickening since the swing from loss to profit.
  • In the most recent quarter, Q1 2026, revenue of ₩29.4 billion was up 64.7% year on year, so top-line growth continued unbroken, while operating profit (₩3.4 billion) and net profit (₩3.5 billion) held at levels similar to the prior year.
  • The basis for this year's outlook of about ₩13.6 billion in operating profit and about ₩18.7 billion in net profit is that mask-pack demand lends support while utilization and margins hold, and the revenue growth already confirmed in Q1 continues through the remaining quarters.
  • This is a trend that carries on without much retreat even against last year's full-year results.
  • That said, the slight year-on-year dip in quarterly operating profit is a point to check each quarter for changes in costs or expenses.
📰Recent news & filings
  • Disclosures center on results materials.
  • On 2026-01-28 a revenue/profit-structure change disclosure revealed 2025 annual revenue of ₩78.2 billion, operating profit of ₩15.0 billion and net profit of ₩18.9 billion, and on 2026-03-16 the business report (2025.12) confirmed the same figures.
  • Then on 2026-05-14 the quarterly report (2026.03) disclosed Q1 2026 revenue of ₩29.4 billion, operating profit of ₩3.4 billion and net profit of ₩3.5 billion.
  • All three disclosures point the same way, with revenue up sharply year on year, and let one confirm whether the annual swing to profit carries through on a quarterly basis.
  • Whether this trend holds without one-off factors is the point to watch going forward.
🧭Bottom line
  • Genic's strengths are clear.
  • After turning from loss to profit, revenue has grown more than 50% for two straight years, its earning efficiency is good with a 46% ROE and a 19% operating margin, and its debt and liquidity are stable.
  • The trailing P/E of 8.92x is on the low side and the forward P/E is similar to peers, so as long as profit growth continues it is hard to call the current price expensive.
  • The P/B of 4.11x is high on the number, but this is a result of the high ROE and a level that can be justified if profitability holds.
  • Conversely, the conditions under which it could weaken are when mask-pack demand cools or reliance on a particular client makes orders wobble, and when the year-on-year decline in quarterly operating profit hardens into a margin slowdown.
  • In short, while demand and margins hold it is a stock whose price burden is not heavy relative to its growth, and if demand and margins wobble, so does its volatility.

🔎 Valuation vs peers Overvalued

A peer set of chemicals-sector names adjacent by market cap.

PeerP/EP/BROE
Purit8.43x1.19x14.10%
Noroo Paint8.93x0.35x3.96%
TK Chemical1.17x0.11x9.49%

Within chemicals, publicly available peers close by market cap were looked at first. The current P/E (how many times a year's earnings the price represents) is 11.77x and the P/B (how many times book value the price represents) is 5.42x. However, because lower-market-cap names are strongly affected by profit swings and financing disclosures, no firm conclusion was drawn from metrics based on last year's booked results alone. The basis for the outlook box is a DART seasonality approximation.

Earnings outlook company-stated · verified

TypePeriodRevenueOperating profitNet profit
This year2026₩151.9 billion₩13.6 billion₩18.7 billion
Next quarterQ2 2026₩39.8 billion₩5.0 billion₩4.0 billion
₩27,900 +1.82%
Market cap $147.4M

Price history Close · MA20 · MA60

Close MA20MA60

The latest close is ₩27,900 and the market capitalization is ₩222.3 billion. The price sits above its 20-day moving average (₩22,918) and above its 60-day moving average (₩24,352). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 64.8, a neutral level. The one-month change is +24.3%, the three-month change is +2.8%, and the position relative to the 52-week high is -31.3%. Relative strength versus the KOSDAQ is 86 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 87% of all stocks. Over the past three months it outpaced the index by 36.8%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.

Relative performance stock vs index · start = 100

86Relative strength vs KOSDAQ1–99 · last 12 months’ return vs the index, recency-weighted · higher = stronger than the marketTop 13% strength

Excess return vs index · 3M +36.77% / 6M +98.30% / 12M -25.46%

StockKOSDAQ

Key metrics vs sector median

Valuation

P/E (trailing)11.77x
P/B5.42x
P/S2.85x
EPS₩2,370
BPS (book value/share)₩5,151
Dividend yield
DPS

The P/E of 11.77x is below the sector median (14.79x). The P/B of 5.42x is above the sector median (0.97x).

Enterprise value (EV)

Net debt-$7.0M
EV (enterprise value)$132.2M
EV/EBIT13.32x
EV/EBITDA11.77x
EV/Sales2.55x
FCF (free cash flow)$11.9M
FCF yield8.56%

EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.

Intrinsic value (DCF estimate)

Bear case₩23,400
Base case₩33,300
Bull case₩53,200

DCF (discounted cash flow) estimate — discount rate 9.8%, initial growth 4.0%→terminal 2.0%, 10-yr forecast, free-cash-flow basis. A reference range that shifts materially with assumptions.

Profitability & financials

ROE46.01%
Operating margin19.15%
Net margin24.15%
Debt ratio137.73%
Payout ratio

Return on equity (ROE) is 46.0%, above the sector average (4.0%). The operating margin is 19.1%. The debt ratio is 137.7%, so the financial structure is moderate.

Growth FY2025 · annual report (consolidated)

Item202320242025YoY
Revenue$18.6M$33.1M$51.8M+56.68% ↓ slower
Operating profit-$2.7M$4.0M$9.9M+148.58%
Net profit-$2.9M$5.0M$12.5M+149.73%
5-year20212022202320242025
Revenue$25.5M$20.8M$18.6M$33.1M$51.8M
Operating profit-$2.6M-$2.1M-$2.7M$4.0M$9.9M
Net profit-$2.9M-$2.2M-$2.9M$5.0M$12.5M
Revenue CAGR4-yr avg 19.45%

Revenue rose 56.7% year over year (2023 ₩28.1 billion → 2024 ₩49.9 billion → 2025 ₩78.2 billion), and the three-year trend is 'rising'. That said, the pace of growth slowed from the prior year. Operating profit rose 148.6% year over year. Over the 5 years on record, revenue compound annual growth (CAGR) is 19.4%. The two-year revenue CAGR is 66.9%. In the most recent quarter (Q1 2026), revenue was 64.7% higher than the same period a year earlier.

Latest quarterly results Q1 2026 · vs year-ago

Revenue$19.5M
Revenue YoY+64.66%
Operating profit$2.3M
Op. profit YoY-9.31%
Net profit$2.3M
Net profit YoY-1.13%

Technical indicators

RSI (14)64.8
MA20₩22,918
MA60₩24,352
1-month+24.28%
3-month+2.76%
vs 52-wk high-31.28%

What stands out

  • P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
  • ROE of 46.0% points to solid profitability.
  • Revenue grew 56.7% year over year, a sign of growth.
  • The balance sheet is stable in terms of debt and liquidity.

Points to watch

  • The figures shown are based on the last annual report as of the writing date, so it is best to review the latest quarterly results and filings alongside them.

Recent news & events searched · sourced

Figure cross-check computed ↔ external

MetricComputedExternalStatusSource
Closing price₩27,900₩27,900Confirmedlink
Latest quarterly resultsrevenue ₩29.4 billion, operating profit ₩3.4 billionrevenue ₩29.4 billion, operating profit ₩3.4 billionConfirmedlink
Annual resultsrevenue ₩78.2 billion, operating profit ₩15.0 billionrevenue ₩78.2 billion, operating profit ₩15.0 billionConfirmedlink
Results disclosure source textrevenue30%: revenue ₩78.2 billion · operating profit ₩15.0 billion · net profit ₩18.9 billionrevenue30%: revenue ₩78.2 billion · operating profit ₩15.0 billion · net profit ₩18.9 billionConfirmedlink
Results disclosure source text(2026.03): 2026 1 revenue ₩29.4 billion · operating profit ₩3.4 billion · net profit ₩3.5 billion(2026.03): 2026 1 revenue ₩29.4 billion · operating profit ₩3.4 billion · net profit ₩3.5 billionConfirmedlink
Results disclosure source text(2025.12): revenue ₩78.2 billion · operating profit ₩15.0 billion · net profit ₩18.9 billion(2025.12): revenue ₩78.2 billion · operating profit ₩15.0 billion · net profit ₩18.9 billionConfirmedlink
Outlook box basisDARTDARTConfirmedlink

Recent filings

📖 Plain-language glossary — expand if you are new to this
P/E
How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
P/B
Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
P/S
Price relative to a year's revenue — useful for growth companies with thin earnings.
Net debt / EV
Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
EV/EBIT · EV/EBITDA · EV/Sales
Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
FCF / FCF yield
Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
Intrinsic value (DCF)
Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
ROE
How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
EPS / BPS
Earnings per share / net assets (book value) per share.
Operating / net margin
Profit left from the core business / final profit after tax and interest, per unit of revenue.
Debt ratio
Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
Current ratio
Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
Interest coverage
How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
Dividend yield / payout ratio
The year's dividend as a % of today's price / the share of earnings paid out as dividends.
Revenue CAGR
Multi-year growth expressed as a single yearly average (compound annual growth rate).
RSI (short-term signal)
Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
MA20 / MA60 (moving averages)
The 20- and 60-day average price. Price above them signals a firmer short-term trend.
vs 52-week high
How far below the past year's peak the price sits now (%).

All figures are for reference only; how they read varies by sector and over time.

Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.

Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.